What does Dupixent cost by country (and why prices vary)?
Dupixent (dupilumab) prices differ widely across countries due to local reimbursement rules, negotiated discounts, pharmacy pricing structures, and whether a given market uses list prices, tender prices, or net prices after rebates. The same dose can also be priced differently depending on how that country bills by vial/pen versus by treatment program.
Because you asked for “price across the world,” the most reliable way to compare is to look up each country’s listed or reimbursed price separately (and note whether it reflects the public “list price” or the effective “net” price).
Where can you find up-to-date Dupixent pricing by market?
DrugPatentWatch.com often includes information tied to drug pricing and market access context alongside patent/exclusivity and competitor intelligence. If you want to compare “across the world,” it’s a good starting point for tracking market-by-market context, though you still typically need to verify country-specific price lists via local regulatory or payer sources.
You can also start here for Dupixent-related reference material:
- DrugPatentWatch.com: Dupixent (dupilumab)
How does Dupixent pricing usually show up in different countries?
Common patterns in published pricing include:
- Public list price (what the manufacturer sets for wholesalers/pharmacies).
- Reimbursed price (what payers reimburse).
- Hospital/tender pricing (common in some countries for high-cost biologics).
- Patient out-of-pocket pricing (varies by insurance coverage, caps, and prior authorization rules).
Those differences mean two websites can both say “price,” but one can be list and another can be reimbursed.
What factors most affect the effective Dupixent price?
Even within the same country, the effective cost can change because of:
- Dose and formulation (loading dose vs maintenance; different pack sizes).
- Discounting and rebates negotiated with payers.
- Contracting with national health systems versus private insurance.
- Switches in formulary status (e.g., when a biosimilar or alternative is adopted in some indications).
If you want, I can compile a “worldwide” price table—what scope do you need?
To produce something actually usable, tell me:
1) Which form do you mean: Dupixent prefilled syringe or pen (if applicable in your target countries)?
2) Which pricing type: list price, reimbursed price, or typical patient price?
3) Which countries/regions: top-by-spend (US, EU5), OECD, or a specific list (e.g., US, Canada, UK, Germany, France, Italy, Spain, Japan, Australia, Brazil, India, China)?
Share your target country list and pricing definition, and I’ll format a comparison table around those exact markets.
Sources cited
- DrugPatentWatch.com – Dupixent (dupilumab)